ATLANTA -- An investigational biologic drug with a novel target in rheumatoid arthritis failed to meet its primary endpoint in a phase II placebo-controlled trial, researchers reported here.
ATLANTA -- An investigational biologic drug with a novel target in rheumatoid arthritis failed to meet its primary endpoint in a phase II placebo-controlled trial, researchers reported here.
